|Table of Contents|

Clinical and pathological characteristics analysis of Hobnail variant of papillary thyroid carcinoma (25 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 04
Page:
648-652
Research Field:
Publishing date:

Info

Title:
Clinical and pathological characteristics analysis of Hobnail variant of papillary thyroid carcinoma (25 cases)
Author(s):
TAN Zhihui; JIA Hao; TANG Xuefeng
Department of Pathology,Chongqing People's Hospital,Chongqing 400000,China.
Keywords:
papillary thyroid carcinoma; Hobnail variant; affected central lymph nodes; metastatic tumor size
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2025.04.015
Abstract:
Objective:To investigate the clinical pathology characteristics of Hobnail variant of papillary thyroid carcinoma(HV-PTC),and to provide the basis for clinical operation and precise treatment,and to reduce the second operation rate and long-term mortality.Methods:Retrospective analysis of 2 945 cases of papillary thyroid carcinoma (PTC) 2021 in the department of pathology of our hospital in 2022.All cases underwent unilateral lobectomy of thyroid gland and lymph node dissection of the affected side in central district,according to the postoperative pathological results,the patients were divided into three groups:HV-PTC group,classical of papillary thyroid carcinoma (c-PTC) group and c-PTC+HV group,analyze the clinical pathology signature of the HV-PTC.Results:There were 25 cases in the HV-PTC group,146 cases in the c-PTC+HV group,and 2 774 cases in the c-PTC group among 2 945 PTC cases.A comparative study between the HV-PTC group and the c-PTC+HV group and the c-PTC group showed no significant changes in the age of diagnosis and the number of lesions(P＞0.05).The tumor diameter in the HV-PTC group and c-PTC+HV group was larger than that in the c-PTC group(P=0.000 2,P＜0.000 1),and the incidence of lymph node metastasis in the central region of the affected side was higher than that in the c-PTC group(P=0.009 9,P＜0.000 1).The size of cancer metastasis in the lymph nodes of the c-PTC+HV group was larger than that of the c-PTC group(P＜0.000 1).Conclusion:HV-PTC typically has a larger diameter of the primary lesion,a higher rate of lymph node metastasis in the affected central district,and a larger,more aggressive metastatic lesion compared with c-PTC.

References:

［1］SHAO L,SUN W,ZHANG H,et al.Risk factors for right paraesophageal lymph node metastasis in papillary thyroid carcinoma:A meta-analysis［J］.Surg Oncol,2020,32:90-98.
［2］丁培森，刘思雨，邢志磊，等.基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析［J］.天津医药，2024,29(2):1-6. DING PS,LIU SY,XING ZL,et al.Visual analysis of thyroid cancer molecules and cell biology based on VOS viewer［J］.Tianjin Medicine,2024,29(2):1-6.
［3］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［4］李小磊，庄大勇，贺青卿，等.肿瘤直径>1 cm甲状腺乳头状癌的淋巴结转移规律及危险因素分析［J］.中国肿瘤外科杂志，2020,12(05):387-391. LI XL,ZHUANG DY,HE QQ,et al.Analysis of lymph node metastasis and risk factors in papillary thyroid carcinoma with tumor diameter>GT.1 cm［J］.Chinese Journal of Oncology Surgery,2020,12(05):387-391.
［5］韩静静，温晓文，王雅莉，等.甲状腺乳头状癌开放式手术后患者体像认知现状及影响因素分析［J］.山东大学耳鼻喉眼学报，2024,17(01):1-8. HAN JJ,WEN XW,WANG YL,et al.Analysis of status quo and influencing factors of body image cognition in patients with thyroid papillary carcinoma after open surgery［J］.Journal of Otorhinolaryngology of Shandong University,2024,17(01):1-8.
［6］ASIOLI S,ERICKSON LA,SEBO TJ,et al.Papillary thyroid carcinoma with prominent hobnail features:a new aggressive variant of moderately differentiated papillary carcinoma.A clinicopathologic,immunohistochemical,and molecular study of eight cases［J］.Am J Surg Pathol,2010,34(1):44-52.
［7］黄慧婷，牟虹.鞋钉样亚型甲状腺乳头状癌的临床病理特征［J］.浙江实用医学，2020,25(04):291-294. HUANG HT,MOU H.Clinicopathological features of shoestring-like thyroid papillary carcinoma ［J］.Zhejiang Practical Medicine,2020,25(04):291-294.
［8］张海东，龚单春，梁思萍，等.晚期甲状腺乳头状癌鞋钉亚型1例［J］.中华耳鼻咽喉头颈外科杂志，2023,58(01):72-74. ZHANG HD,GONG DC,LIANG SP,et al.One case of shoe stud subtype of advanced papillary thyroid carcinoma［J］.Chinese Journal of Otorhinolaryngology Head and Neck Surgery,2023,58(01):72-74.
［9］LLOYD RV,OSAMURA R,KLOPPEL G,et al.WHO classification of tumours of endocrine organs,4th ed［M］.Lyon:WHO,2017:181-246.
［10］WANG LY,VERSNICK MA,GILL AJ,et al.Level VII is an important component of central neck dissection for papillary thyroid cancer［J］.Ann Surg Oncol,2013,20(7):2261-2265.
［11］张晓梅，李巧莉，葛肖艳，等.基于常规超声联合超声造影的列线图预测临床淋巴结阴性甲状腺乳头状癌中央区淋巴结转移［J］.中国医学影像学杂志，2024,32(01):28-33,41. ZHANG XM,LI QL,GE XY,et al.Prediction of lymph node metastasis in patients with clinically node-negative papillary thyroid carcinoma in central district based on nomograms of conventional ultrasound combined with contrast-enhanced ultrasound［J］.Chinese Journal of Medical Imaging,2024,32(01):28-33,41.
［12］ LI J,SUN P,HUANG T,et al.Preoperative prediction of central lymph node metastasis in cN0T1/T2 papillary thyroid carcinoma:A nomogram based on clinical and ultrasound characteristics［J］.Eur J Surg Oncol,2022,48(6):1272-1279.
［13］SHAHA AR.Central lymph node metastasis in papillary thyroid carcinoma［J］.World Journal of Surgery,2018,42(3):630-631.
［14］葛明华，高明，程若川，等.中国肿瘤整合诊治指南.甲状腺癌［M］.天津:天津科学技术出版社，2022:1-138. GE MH,GAO M,CHENG RC,et al.Chinese guidelines for integrated diagnosis and treatment of cancer.Thyroid cancer［M］.Tianjin:Tianjin Science and Technology Press,2022:1-138.
［15］ JEON MJ,YOON JH,HAN JM,et al.The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma［J］.Eur J Endocrinol,2013,168(2):219-225.
［16］KANG IK,PARK J,BAE JS,et al.Lymph node ratio predicts recurrence in patients with papillary thyroid carcinoma with low lymph node yield［J］.Cancers (Basel),2023,15(11):2947.
［17］KIM SY,KIM BW,PYO JY,et al.Macrometastasis in papillary thyroid cancer patients is associated with higher recurrence in lateral neck nodes［J］.World J Surg,2018,42(1):123-129.
［18］中华人民共和国国家卫生健康委员会医政医管局.甲状腺癌诊疗指南（2022年版）［J］.中国实用外科杂志，2022,42(12):1343-1357,1363. Medical Administration of the State Health Commission of the People's Republic of China.Thyroid Cancer Guidelines(2022 edition)［J］.Chinese Journal of Practical Surgery,2022,42(12):1343-1357,1363.
［19］LIU Q,JIANG X,TU W,et al.Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)［J］.Exp Ther Med,2024,27(4):149.
［20］周瑞瑜，吴立强，罗以.BRAF V600E基因突变与甲状腺乳头状癌远处转移及预后的关系［J］.肿瘤药学，2022,12(03):387-390. ZHOU RY,WU LQ,LUO Y.Association of BRAF V600E gene mutation with distant metastasis and prognosis in papillary thyroid carcinoma ［J］.Oncology Pharmacy,2022,12(03):387-390.
［21］ LIU CP,CHEN TW,LIU ZM.Associations between BRAF V600E and prognostic factors and poor outcomes in papillary thyroid carcinoma:a meta-analysis［J］.World J Surg Onc,2016,14:241.
［22］XING MZ,ALZAHRANI AS,CARSON KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer［J］.JAMA,2013,309(14):1493-1501.
［23］BUI DANG MINHT,NGHIEM DUC T,PHAN NGUYEN THANH V,et al.Relationships of BRAF V600E gene mutation with some immunohistochemical markers and recurrence rate in patients with thyroid carcinoma［J］.Clin Med Insights Oncol,2023,17:11795549231203503.

Memo

Memo:
-
Last Update: 1900-01-01